A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus

Drugs and Aging

Volumn 34, Issue 1, 2017, Pages 29-38

  Heise, Tim ^a   Hövelmann, Ulrike ^a   Zijlstra, Eric ^a   Stender Petersen, Kirstine ^b   Jacobsen, Jacob Bonde ^b   Haahr, Hanne ^b  

^a Profil Institut fur Stoffwechselforschung GmbH   (Germany)

^b NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; INSULIN ASPART; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; SHORT ACTING INSULIN;

ADULT; AGE DISTRIBUTION; AGED; ALGORITHM; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFECT; DRUG RELEASE; DRUG SAFETY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; OSCILLATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; ADOLESCENT; AGING; ANALYSIS; BLOOD; CHEMISTRY; DIABETES MELLITUS, TYPE 1; DOSE RESPONSE; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; MEDICINAL CHEMISTRY; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGING; BLOOD GLUCOSE; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN ASPART; INSULIN, SHORT-ACTING; MALE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84996484005     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-016-0418-6     Document Type: Article

References (28)

1. Heller S, McCance DR, Moghissi E, Nazeri A, Kordonouri O. Diversity in diabetes: the role of insulin aspart. Diabetes Metab Res Rev. 2012;28:50–61.
2. US Food and Drug Administration. Inactive ingredient search for approved drug products. http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm. Accessed 7 Oct 2016.
3. Heise T, Hövelmann U, Brøndsted L, Adrian CL, Nosek L, Haahr H. Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Diabetes Obes Metab. 2015;17:682–8.
4. Heise T, Stender-Petersen K, Hövelmann U, et al. Pharmacokinetic and pharmacodynamic properties of faster-acting insulin aspart versus insulin aspart across a clinically relevant dose range in subjects with type 1 diabetes mellitus. Clinical Pharmacokinet. doi:10.1007/s40262-016-0473-5.
5. Heise T, Pieber TR, Danne T, Erichsen L, Haahr H. Faster onset and greater early exposure and glucose-lowering effect with faster-acting insulin aspart vs. insulin aspart: a pooled analysis in subjects with type 1 diabetes [abstract]. Diabetes. 2016;65(Suppl. 1):A239.
6. ® 1 trial [abstract]. Diabetes. 2016;65(Suppl. 1):A77.
7. ® 2 trial [abstract]. Diabetes. 2016;65(Suppl. 1):A63.
8. ICH Harmonised Tripartite Guideline E7. Studies in support of special populations: geriatrics. 24 June 1993. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E7/Step4/E7_Guideline.pdf. Accessed 7 Oct 2016.
9. ICH. E7 studies in support of special populations: geriatrics. Questions & answers. 6 July 2010. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E7/Q_As/E7_Q_As_step4.pdf. Accessed 7 Oct 2016.
10. European Medicines Agency. Committee for Medicinal Products for Human Use. Adequacy of Guidance on the Elderly Regarding Medicinal Products for Human Use. 14 December 2006. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500049541.pdf. Accessed 7 Oct 2016.
11. Benesch C, Heise T, Klein O, Heinemann L, Arnolds S. How to assess the quality of glucose clamps? Evaluation of clamps performed with ClampArt, a novel automated clamp device. J Diabetes Sci Technol. 2015;9:792–800.
12. American Diabetes Association. Defining and reporting hypoglycaemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycaemia. Diabetes Care. 2005;28:1245–9.
13. Fieller EC. Some problems in interval estimation. J R Stat Soc Ser B Stat Methodol. 1954;16:175–85.
14. Clemens AH, Hough DL, D’Orazio PA. Development of the Biostator glucose clamping algorithm. Clin Chem. 1982;28:1899–904.
15. Thompson AM, Linnebur SA, Vande Griend JP, Saseen JJ. Glycemic targets and medication limitations for type 2 diabetes mellitus in the older adult. Consult Pharm. 2014;29:110–23.
16. Ligthelm RJ, Kaiser M, Vora J, Yale JF. Insulin use in elderly adults: risk of hypoglycemia and strategies for care. J Am Geriatr Soc. 2012;60:1564–70.
17. Meneilly GS. A comparison of insulin aspart and regular insulin in elderly patients with type 2 diabetes. Diabetes Obes Metab. 2007;9:754–5.
18. Velussi M. Lispro insulin treatment in comparison with regular human insulin in type 2 diabetic patients living in nursing homes. Diabetes Nutr Metab. 2002;15:96–100.
19. Brunner M, Pieber T, Korsatko S, Kojzar H, Svendsen AL, Haahr H. The distinct prandial and basal pharmacodynamics of IDegAsp observed in younger adults are preserved in elderly subjects with type 1 diabetes. Drugs Aging. 2015;32:583–90.
20. Korsatko S, Deller S, Mader JK, et al. Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus. Drugs Aging. 2014;31:47–53.
21. ® [prescribing information]. February 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021536s031s051lbl.pdf. Accessed 7 Oct 2016.
22. Minaker KL, Rowe JW, Tonino R, Pallotta JA. Influence of age on clearance of insulin in man. Diabetes. 1982;31:851–5.
23. Kalyani RR, Egan JM. Diabetes and altered glucose metabolism with aging. Endocrinol Metab Clin N Am. 2013;42:333–47.
24. Defronzo RA. Glucose intolerance and aging: evidence for tissue insensitivity to insulin. Diabetes. 1979;28:1095–101.
25. Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults. Diabetes Care. 2012;35:2650–64.
26. Tanwani LK. Insulin therapy in the elderly patient with diabetes. Am J Geriatr Pharmacother. 2011;9:24–36.
27. Ober SK, Watts S, Lawrence RH. Insulin use in elderly diabetic patients. Clin Interv Aging. 2006;1:107–13.
28. Krones R, Schütte C, Heise T. The rapid-acting properties of insulin aspart are preserved in elderly people with type 2 diabetes. Diabetes Obes Metab. 2009;11:41–4.